Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1.-53. (Canceled)

54. (Currently amended) A method of treating a subject having ~~a disorder characterized by unwanted cell proliferation~~ an angiogenesis-dependent tumor, the method comprising:

identifying a subject having ~~a disorder characterized by unwanted cell proliferation~~ an angiogenesis-dependent tumor; and

administering to the subject a cell expressing a TSP-2 comprising an amino acid sequence at least 95% identical to the sequence of SEQ ID NO:2, or a ~~functional~~ fragment thereof, capable of inhibiting endothelial cell migration, wherein the fragment comprises at least 10 contiguous amino acids of either a procollagen domain of TSP-2 or a type I repeat of TSP-2.

55. (Currently amended) The method of claim 54, wherein the cell is a genetically engineered cell modified to cause the expression of the TSP-2 or the ~~functional~~ fragment thereof.

56. (Previously presented) The method of claim 55, wherein the cell has been genetically modified to introduce a regulatory sequence that causes or increases the expression of an endogenous TSP-2 gene.

57. (Currently Amended) The method of claim 55, wherein the cell comprises an exogenous nucleic [[aid]] acid encoding the TSP-2 or the ~~functional~~ fragment thereof.

58. (Previously presented) The method of claim 55, wherein the cell is autologous.

59. (Previously presented) The method of claim 56, wherein the cell is autologous.

60. (Previously presented) The method of claim 57, wherein the cell is autologous.

61. (Previously presented) The method of claim 55, wherein the cell is allogeneic.

62. (Previously presented) The method of claim 56, wherein the cell is allogeneic.

63. (Previously presented) The method of claim 57, wherein the cell is allogeneic.

64. (Previously presented) The method of claim 55, wherein the cell is xenogeneic.

65. (Previously presented) The method of claim 56, wherein the cell is xenogeneic.

66. (Previously presented) The method of claim 57, wherein the cell is xenogeneic.

67. (Previously presented) The method of claim 56, wherein the promoter of the endogenous TSP-2 gene has been replaced by a promoter from another gene.

68. (Previously presented) The method of claim 54, 55, 56 or 57, wherein the cell is an epithelial cell.

69. (Previously presented) The method of claim 54, 55, 56 or 57, wherein the cell is selected from the group consisting of: a fibroblast, a keratinocyte, an endothelial cell, a glial cell, a neural cell, a lymphocyte, a bone marrow cell, and a muscle cell.

70. (Previously presented) The method of claim 55, wherein the level of TSP-2 in the subject after administration is increased for at least 2 days.

71. (Previously presented) The method of claim 55, wherein the level of TSP-2 in the subject after administration is increased for at least 10 days.

72. (Previously presented) The method of claim 55, wherein the level of TSP-2 in the subject after administration is increased for at least 14 days.

73. (Previously presented) The method of claim 55, wherein the level of TSP-2 in the subject after administration is increased for at least 30 days.

74. (Canceled)

75. (Currently amended) The method of claim [[74]] 55, wherein the ~~disorder~~ tumor is selected from the group consisting of: melanoma, a prostate ~~cancer~~ tumor, a breast ~~cancer~~ tumor, a colon ~~cancer~~ tumor, and a lung ~~cancer~~ tumor.

76. (Previously presented) The method of claim 54, wherein the subject is a human.

77. (Previously presented) The method of claim 55, wherein the subject is a human.

78. (Previously presented) The method of claim 56, wherein the subject is a human.

79. (Previously presented) The method of claim 57, wherein the subject is a human.

80. (Canceled)

81. (Currently amended) A method of treating a subject having ~~a disorder characterized by unwanted cell proliferation~~ an angiogenesis-dependent tumor, the method comprising:

identifying a subject having ~~a disorder characterized by unwanted cell proliferation~~ an angiogenesis-dependent tumor; and

administering to the subject a cell ~~expressing~~ genetically engineered to express a TSP-2 comprising an amino acid sequence encoded by a nucleotide sequence that hybridizes to the nucleotide sequence of ~~SEQ ID NO:2~~ SEQ ID NO:1 under the hybridization conditions of: hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65°C, or a ~~functional~~ fragment thereof, capable of inhibiting endothelial cell migration, wherein the fragment comprises at least 10 contiguous amino acids of either a procollagen domain of TSP-2 or a type I repeat of TSP-2.

82. (Currently amended) A method of treating a subject having ~~a disorder characterized by unwanted cell proliferation~~ an angiogenesis-dependent tumor, the method comprising:

identifying a subject having ~~a disorder characterized by unwanted cell proliferation~~ an angiogenesis-dependent tumor; and

administering to the subject a cell genetically engineered to ~~expressing~~ express TSP-2 (SEQ ID NO:2) or a fragment thereof, capable of inhibiting endothelial cell migration, wherein the fragment comprises at least 10 contiguous amino acids of either a procollagen domain of TSP-2 or a type I repeat of TSP-2.

83. (Previously presented) The method of claim 54, wherein the TSP-2 is at least 97% identical to the sequence of SEQ ID NO:2.

84. (Previously presented) The method of claim 54, wherein the TSP-2 is at least 98% identical to the sequence of SEQ ID NO:2.

85. (Previously presented) The method of claim 54, wherein the TSP-2 is at least 99% identical to the sequence of SEQ ID NO:2.

86. (New) The method of claim 82, wherein the cell is a genetically engineered cell modified to cause the expression of the TSP-2.

87. (New) The method of claim 86, wherein the cell is autologous.

88. (New) The method of claim 86, wherein the cell is allogeneic.

89. (New) The method of claim 86, wherein the cell is xenogeneic.

90. (New) The method of claim 82 or 86, wherein the cell is an epithelial cell.

91. (New) The method of claim 82 or 86, wherein the cell is selected from the group consisting of: a fibroblast, a keratinocyte, an endothelial cell, a glial cell, a neural cell, a lymphocyte, a bone marrow cell, and a muscle cell.

92. (New) The method of claim 86, wherein the level of TSP-2 or fragment thereof in the subject after administration is increased for at least 2 days.

93. (New) The method of claim 86, wherein the level of TSP-2 in the subject after administration is increased for at least 10 days.

94. (New) The method of claim 86, wherein the level of TSP-2 in the subject after administration is increased for at least 14 days.

95. (New) The method of claim 86, wherein the level of TSP-2 in the subject after administration is increased for at least 30 days.

96. (New) The method of claim 82, wherein the tumor is selected from the group consisting of: melanoma, a prostate tumor, a breast tumor, a colon tumor, and a lung tumor.

D1 Conclude

97. (New) The method of claim 82, wherein the subject is a human.

98. (New) The method of claim 86, wherein the subject is a human.

99. (New) A method of treating a subject having an angiogenesis-dependent tumor, the method comprising:

administering to the subject a cell expressing TSP-2 (SEQ ID NO:2).